Emily Quick
Pulmonary Disease · Flemington, NJNPI 1568049872
Payments from drug & device makers
Across 114 payments — averaging $25.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$251
- Regeneron Healthcare Solutions, Inc.$178
- Novo Nordisk$146
- Takeda Pharmaceuticals U.S.A., Inc.$139
- Pulmonx Corporation$119
- plus $921 from 22 others
What the payments were for
- Food & beverage$2,869100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 22 | $1,116 |
| GSK | 13 | $251 |
| Regeneron Healthcare Solutions, Inc. | 11 | $178 |
| Novo Nordisk | 5 | $146 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $139 |
| Pulmonx Corporation | 1 | $119 |
| Axsome Therapeutics, Inc. | 6 | $97 |
| Electromed, Inc. | 7 | $80 |
| Inspire Medical Systems, Inc. | 3 | $77 |
| Harmony Biosciences LLC | 4 | $76 |
| Baxter Healthcare | 3 | $69 |
| Verona Pharma, Inc. | 3 | $56 |
| Sanofi | 3 | $54 |
| AbbVie | 3 | $48 |
| Amgen | 3 | $48 |
| SK Life Science, Inc. | 2 | $36 |
| Xeris Pharmaceuticals, Inc. | 2 | $35 |
| Mylan Specialty L.p. | 2 | $34 |
| United Therapeutics Corporation | 2 | $33 |
| Boehringer Ingelheim | 2 | $32 |
| Jazz Pharmaceuticals Inc. | 2 | $28 |
| Grifols USA, LLC | 1 | $19 |
| Johnson & Johnson | 1 | $19 |
| Argenx US, Inc. | 1 | $18 |
| Insmed, Inc. | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $16 |
| Merck | 1 | $15 |
| Philips North America LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEZSPIRE$521
- FASENRA$272
- AIRSUPRA$151
- BREZTRI$130
- CHARTIS CATHETER$119
- ZEPHYR DELIVERY CATHETER$119
- ZEPHYR ENDOBRONCHIAL VALVE$119
- PULMONX CHARTIS TABLET CONSOLE$119
How this compares
$2,869 in reported general payments places this provider in the 50th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 199 | $155,988 |
| Dupixent PenDupilumab | 19 | $53,233 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 47 | $36,007 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 45 | $29,733 |
| Breo ElliptaFluticasone/Vilanterol | 46 | $22,637 |
| EliquisApixaban | 27 | $17,950 |
| Spiriva RespimatTiotropium Bromide | 16 | $15,039 |
| XareltoRivaroxaban | 15 | $12,895 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 48 | $6,449 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $4,327 |
| DuleraMometasone/Formoterol | 11 | $3,485 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 97 | $3,105 |
| Ventolin HfaAlbuterol Sulfate | 18 | $1,427 |
| Bumetanide | 12 | $1,398 |
| Ipratropium Bromide | 20 | $582 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $251 | $212,685303 claims |
| AstraZenecaBreztri Aerosphere | $1,116 | $36,00747 claims |
| Boehringer IngelheimSpiriva Respimat | $32 | $15,03916 claims |
| Johnson & JohnsonXarelto | $19 | $12,89515 claims |
| MerckDulera | $15 | $3,48511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in Flemington
- Reynold PanettieriNew Brunswick$2.5M
- Vinay SikandToms River$1.8M
- Stanley FielMorristown$1.3M
- Joseph HoffmanPark Ridge$1.1M
- Robert SussmanSummit$645K
- Ronaldo GoHackensack$563K
- Deborah GossHackensack$558K
- Sabina HussainNew Brunswick$555K
- Manuel CunananMillville$489K
- Emanuele SantomauroHackensack$420K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.